G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genovis AB
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Deferred Income Tax
kr2m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Deferred Income Tax
kr415m
CAGR 3-Years
37%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Deferred Income Tax
kr224.5m
CAGR 3-Years
56%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Deferred Income Tax
kr187m
CAGR 3-Years
72%
CAGR 5-Years
43%
CAGR 10-Years
57%
MedCap AB (publ)
STO:MCAP
Deferred Income Tax
kr62.9m
CAGR 3-Years
18%
CAGR 5-Years
19%
CAGR 10-Years
9%
M
Magle Chemoswed Holding AB
STO:MAGLE
Deferred Income Tax
kr8.6m
CAGR 3-Years
60%
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Deferred Income Tax?
Deferred Income Tax
2m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Deferred Income Tax amounts to 2m SEK.

What is Genovis AB's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 3Y
-6%

Over the last year, the Deferred Income Tax growth was -17%. The average annual Deferred Income Tax growth rates for Genovis AB have been -6% over the past three years .

Back to Top